Health Care Supplies

STAAR Surgical

STAAR Surgical released FY2026 Q1 earnings on May 13 After-Market (EST), actual revenue USD 93.52 M (forecast USD 78.72 M), actual EPS USD 0.1 (forecast USD 0.0285)

STAAR Surgical to Release FY2026 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 78.72 M, EPS USD 0.0087

STAAR Surgical released FY2025 annual earnings on March 3 After-Market (EST), actual revenue USD 0 (forecast USD 257.52 M), actual EPS USD 0 (forecast USD -1.1366)

STAAR Surgical released FY2025 Q4 earnings on March 3 After-Market (EST), actual revenue USD 57.8 M (forecast USD 75.05 M), actual EPS USD -0.3679 (forecast USD 0.0411)

STAAR Surgical to Release FY2025 Q4 Earnings on March 3 After-Market EST, Forecast Revenue USD 75.05 M, EPS USD 0.0411

STAAR Surgical released FY2025 9 Months earnings on November 5 (EST), actual revenue USD 181.64 M, actual EPS USD -1.261

STAAR Surgical released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 94.73 M (forecast USD 89.39 M), actual EPS USD 0.1789 (forecast USD 0.0975)

Da Shi Optical Announces Q3 Financial Results

Alcon completes acquisition of STAAR Surgical

Acuity Brands Reports 2025Q2 Earnings and Acquires Davis Optical

STAAR Surgical released FY2025 Semi-Annual earnings on August 6 After-Market EST, actual revenue USD 86.91 M, actual EPS USD -1.44

STAAR Surgical released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 44.32 M (forecast USD 40.92 M), actual EPS USD -0.34 (forecast USD -0.655)

STAAR Surgical to Release FY2025 Q2 Earnings on August 6 After-Market (EST), Forecast Revenue USD 40.92 M, EPS USD -0.655

Jefferies Raises Da Shi Guang Xue Target Price to $21

Canaccord Genuity raises target price for Dashi to $20

STAAR Surgical released FY2025 Q1 earnings on May 7 After-Market EST, actual revenue USD 42.59 M (forecast USD 40.3 M), actual EPS USD -1.1 (forecast USD -0.6927)

STAAR Surgical to Release FY2025 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 40.3 M, EPS USD -0.6927

Dahsh Optics Announces Board Changes and Expands Swiss Production Capacity

Broadwood Partners Acquires 22,189 Shares of Staar Surgical at $17.46 per Share

STAAR Surgical's Q4 2024 Financial Performance Disappoints, Stock Price Drops 24.68%

InMed Pharmaceuticals

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Amesite

Meiwu Tech

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

NextNRG

CN Energy

MetaVia

Generation Income Properties

Co-Diagnostics

STAA

Wall Street Zen upgraded STAAR Surgical (NASDAQ:STAA) from a 'hold' to a 'buy' rating. Other analysts have also raised their price targets, with Stifel Nicolaus increasing it from $18 to $31, and Canaccord Genuity from $27 to $32. The stock opened at $32.07, with a market cap of $1.60 billion. Recent earnings showed a revenue increase of 119.6% year-over-year, with EPS of $0.10, surpassing estimates.

Market Beat

iShares US Medical Devices

SPDR S&P Health Equip

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

STAAR Surgical (NASDAQ:STAA) Upgraded at Wall Street Zen

.DJI

CSCO

SBIO

U.S. stocks rose significantly, with the Dow Jones up 300 points. STAAR Surgical Co (NASDAQ:STAA) shares surged 8.7% to $31.96 after reporting better-than-expected Q1 earnings of 10 cents per share and sales of $93.522 million. Other notable gainers included POET Technologies (+37.3%), Stubhub Holdings (+21.1%), and Cisco Systems (+15.7%). Overall, many stocks experienced substantial increases following positive quarterly results and guidance adjustments.

benzinga_article

Dow Jones Industrial Average

Cisco

Yeti

Stubhub - CL

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Direxion Daily CSCO Bull 2X Shares

Staar Surgical Posts Upbeat Q1 Results, Joins Cisco, Yeti Holdings And Other Big Stocks Moving Higher On Thursday

QUCY

WGRX

DOCS

IPHA

MDXH

In Thursday's pre-market session, several health care stocks experienced significant movements. Alpha Compute (ALP) surged 71.3% to $0.46, while Innate Pharma (IPHA) rose 24.24% to $1.64. Quantum Cyber (QUCY) increased by 23.88% to $1.66, and Staar Surgical (STAA) gained 21.32% to $35.67. Conversely, MDxHealth (MDXH) fell 41.0% to $1.15, and WORK Medical Tech (WOK) dropped 27.9% to $1.99. Other notable losers included Doximity (DOCS) down 23.43% to $17.91 and Wellgistics Health (WGRX) down 17.53% to $0.08. Earnings reports influenced these movements.

Quantum Cyber NV

Alpha Compute

WORK Medical Tech

Wellgistics Health

Doximity

Innate Pharma SA

MDxHealth SA

GT Biopharma

Cormedix

Regenxbio

Sunshine Biopharma

Mainz Biomed NV

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

12 Health Care Stocks Moving In Thursday's Pre-Market Session

STAAR Surgical shares are trading higher after the company reported better-than-expected Q1 financial results.

STAAR Surgical Company's stock price target has been raised to $23.56 from $21.11, indicating a potential downside of about 20%. The forecasts from 9 analysts range from $16 to $33 per share. The consensus rating remains a 'Hold' with 2 Buy ratings, 9 Hold ratings, and no Sell ratings among 11 analysts covering the stock.

TradingView

Factset Research

STAAR Surgical Company Stock 12‑Month Price Target Raised to $23.56, Implies 20% Downside

STAAR Surgical (NASDAQ:STAA) reported quarterly earnings of $0.10 EPS, missing estimates by $0.03. Revenue reached $93.52 million, exceeding expectations of $78.72 million, marking a 119.6% year-over-year increase. The company experienced a negative return on equity of 10.03% and a net margin of -33.60%. Despite strong sales driven by China, management remains cautious on future guidance due to macroeconomic uncertainties. Insider buying activity has increased, with significant purchases made recently. The stock traded at $29.40, with a market cap of $1.46 billion.

Jefferies Financial

STAAR Surgical (NASDAQ:STAA) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Staar Surgical reported strong Q1 2026 financial results, with net sales of $93.5 million, a 19.6% year-over-year increase, driven by sales in China and the U.S. The company launched the EVO plus ICL in China and improved profitability with adjusted EBITDA of $24.4 million. Despite positive performance, management remains cautious about future guidance due to macroeconomic uncertainties. The focus will be on revenue growth, profitability expansion, and operational efficiency.

Alcon

Transcript: Staar Surgical Q1 2026 Earnings Conference Call

POCI

AQST

In Wednesday's after-market session, Staar Surgical (STAA) shares surged 15.3% to $33.9 following Q1 earnings, while Precision Optics (POCI) rose 15.21% to $5.3 after its Q3 report. Other gainers included Aquestive Therapeutics (AQST) up 13.55% to $4.69, and Psyence Biomedical (PBM) up 10.27% to $5.69. Conversely, MDxHealth (MDXH) plummeted 49.2% to $0.99 after its Q1 report, and Doximity (DOCS) fell 17.49% to $19.3 following Q4 earnings. Other notable losers included Sunshine Biopharma (SBFM) and DarioHealth (DRIO).

STAAR Surgical(STAA.US)